Bringing the multi-treatment mindset to life for practitioners and patients
We spoke to Mark Wilson, Senior Vice President, International, Allergan Aesthetics
As the global aesthetics community comes together at this year’s Aesthetics and Anti-Aging Medicine World Congress (AMWC) in Monaco, Allergan Aesthetics arrives with clear intent: to advance combination treatments, strengthen medical education and respond to evolving patient needs worldwide.
Attendees can expect to hear more about AA Signature™ – our portfolio-based approach to multimodal treatment planning – alongside the latest on our continued investment in world-class education through the Allergan Medical Institute (AMI) and MD Codes™. In our first symposium we focus on skin quality as a key component to multimodality using our latest signature look – Skin360 alongside energy-based devices (EBDs). New data that further strengthens our portfolio and supports expansion into new aesthetic categories globally will be presented throughout our symposia.
Our presence highlights our ongoing commitment to AA Signature™ – an approach that primarily responds to a shift in how both practitioners and consumers approach aesthetic treatments and the growing interest in combination treatments.1 As well as addressing a greater focus on skin quality1 alongside structure and definition, it supports an increasing demand for credible education1 to ensure safe, consistent outcomes.
Patients are more informed, more involved and more intentional about the choices they make. (1) Rather than isolated interventions, they are seeking approaches that work together to deliver natural-looking results over time.1 Recognising this shift has shaped Allergan Aesthetics’ broader strategy – one focused on AA Signature™. The approach reflects how both practitioners and consumers are thinking about aesthetics now and in the future.
WHY COMBINATION TREATMENTS ARE THE NORM
Our new global research spans nine countries and more than 12,000 beauty-involved consumers, (1) to better understand how people in today’s culture approach aesthetic treatments.
More than half of respondents reported receiving treatments across multiple categories in the past 12 months,1 including injectables, professional skin treatments and energy-based devices, with older patients more likely to value personalised plans tailored to their goals. (1) 68% expressed interest in approaches that consider multiple areas of the face, rather than focusing on a single concern. (1)
EDUCATION AND SCIENCE AT THE CORE
As the aesthetics landscape continues to evolve, patients are seeking holistic treatment options that deliver natural and subtle results.1 In response, practitioners are expected to combine treatment and safety outcomes over time. (1)
Meeting this shift requires more than a multimodal mindset. It requires a trusted, well-evidenced portfolio, supported by education and science, to enable predictable, consistent results in practice.
Through the Allergan Medical Institute (AMI), Allergan Aesthetics continues to invest in evidence-based education that is reflected through multiple symposia and expert-led discussions. Our ongoing investment in global clinical research, spanning multiple modalities, continues to strengthen our portfolio and support effective implementation. These efforts give practitioners the knowledge, tools and confidence to design holistic, multimodal treatment plans for their patients.
AA SIGNATURE™: MULTIPLE TREATMENT OPTIONS TO MEET PATIENT NEEDS
AA Signature™ was created in partnership with practitioners, in response to shifts in patient behaviour. It is a portfolio-led approach designed to support personalised, multimodal aesthetic strategies using Allergan Aesthetics’ advanced portfolio of high-quality products.
Rather than focusing on individual treatments, AA Signature™ brings together common aesthetic goals, such as skin quality, lift and definition. AA Signature™ empowers practitioners to deliver natural-looking outcomes – helping patients achieve a look that is truly theirs. Their true signature look.
At AMWC, we will explore AA Signature™ with the concept of using other modalities such as energy-based devices alongside our portfolio to optimise results.
SKIN QUALITY AS A KEY ENTRY POINT TO MULTIMODAL TREATMENT PLANS
70% of patients consider professional or prescribed skincare important within a multi-treatment plan. (1) This reflects a clear expectation that skincare will be layered intentionally alongside injectables and energy-based devices, rather than treated as a standalone category.
Treatments that focus on just one layer of the skin rarely make a meaningful difference to how skin ages. A multimodal approach, working across both the surface and the deeper layers could help support hydration, elasticity and texture in a way that works with the skin – not against it. (2)
Skin quality is a foundational element within modern aesthetic regimens, supporting outcomes such as lift and definition. These themes will be explored during our symposium, including how the Skin360 approach helps patients reach their skin’s potential using the Allergan Aesthetics portfolio.
THE EVOLVING ROLE OF HYALURONIC ACID INJECTABLES
Hyaluronic Acid (HA) injectables are a foundational pillar of aesthetic treatment – clinically proven, versatile, and effective. As demand grows for layered, multimodal approaches, global research from Allergan Aesthetics highlights HA’s role as a subtle solution that works alone or alongside other treatments to deliver natural-looking results. (3)
With 84% of consumers saying they want natural-looking results,1 HA continues to underpin clinical excellence for both new and returning patients – now and in the future.
LOOKING AHEAD
Through our portfolio of products and services, we remain committed to helping practitioners achieve their patients’ aspirations. In partnership with practitioners, Allergan Aesthetics is bringing the multi-treatment mindset to life, helping responsibly shape the next chapter of aesthetics.
Notes This is a promotional material produced and funded by Allergan Aesthetics, an AbbVie company, and intended for Healthcare Professionals
References
1. Allergan Aesthetics Holistic Beauty Global Research. REF-145017.
January 2026
2. Presented at the International Master Course on Aging Science World Congress (IMCAS). January 29-31 2026. Paris, France. DV-017943
3. Allergan Aesthetics Future of HA Injectables. ALL-AGNA-250194.
November 2025
Practitioners attending AMWC Monaco can learn more about AA Signature™ and access our latest research through our symposia and via Meet the Expert sessions at the Allergan Aesthetics booth P3. Our new research report can be downloaded on our booth.
AMI Symposia:
Thursday 26 March / 10:45 – 12:45 / Salle des Princes / Grimaldi Forum
Friday 27 March / 09:45 – 12:45 / Salle des Princes / Grimaldi Forum
Global Medical Affairs Symposium:
Friday 27 March / 14:00 – 16:00 / Nijinski Room / Grimaldi Forum
